These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27897411)

  • 1. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch AR; Chua NS; Fontaine A; Sangha R; Turner AR; Baracos VE; Sawyer MB
    PLoS One; 2015; 10(6):e0127589. PubMed ID: 26030144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.
    Niiyama-Uchibori Y; Okamoto H; Miyashita A; Mizuhara K; Kanayama-Kawaji Y; Fujino T; Tsukamoto T; Mizutani S; Shimura Y; Teramukai S; Kuroda J
    Hematol Oncol; 2024 Jan; 42(1):e3252. PubMed ID: 38287527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
    Go SI; Kim HG; Kang MH; Park S; Lee GW
    BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
    Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF
    Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Lanic H; Kraut-Tauzia J; Modzelewski R; Clatot F; Mareschal S; Picquenot JM; Stamatoullas A; Leprêtre S; Tilly H; Jardin F
    Leuk Lymphoma; 2014 Apr; 55(4):817-23. PubMed ID: 23781925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.
    Guan Q; Hong Y; Hu G; Zhou Q; Li L; Qian Z; Zhou S; Ren X; Qiu L; Wang X; Zhang H
    Hematol Oncol; 2021 Oct; 39(4):490-497. PubMed ID: 33908077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma.
    Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC
    Medicine (Baltimore); 2018 Jan; 97(2):e9513. PubMed ID: 29480842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Camus V; Lanic H; Kraut J; Modzelewski R; Clatot F; Picquenot JM; Contentin N; Lenain P; Groza L; Lemasle E; Fronville C; Cardinael N; Fontoura ML; Chamseddine A; Brehar O; Stamatoullas A; Leprêtre S; Tilly H; Jardin F
    Eur J Haematol; 2014 Jul; 93(1):9-18. PubMed ID: 24520908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Monocyte and Platelet Counts May Provide Additional Prognostic Information in Primary Gastric Diffuse Large B-cell Lymphoma Patients Treated with Rituximab and CHOP.
    Spassov B; Vassileva D; Nikolov S; Ganeva P; Balatzenko G; Guenova M
    Folia Med (Plovdiv); 2020 Dec; 62(4):785-801. PubMed ID: 33415923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
    Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.